Partnering trends and predictions 2026
Reserve your seat
With $300 billion in revenue reaching loss of exclusivity by 2030, the pressure on securing the next generation of medicines is palpable. We’re also faced with waves of uncertainty and possibility from AI and geopolitical instabilities.
Biopharma R&D is at an inflection point, and discerning the patterns in partnering from the past year is an essential roadmap to have for navigating the year ahead.
To kick-start 2026, Chris Dokomajilar, Founder and CEO of DealForma, joins Inpart for our annual deep dive into the dealmaking data, with a new focus on earlier-stage interests. Fresh from J.P. Morgan, Chris will help us gather a view on the trajectory of trends from 2025 set to shape a pivotal year for pharma.
This year, Chris is joined by Inpart’s Robin Knight to introduce a new architecture for partnering data, harmonizing assets from multiple data sources with existing pipelines, for active, dynamic landscaping.
Panelists
On the webinar, we will shine a light on:
- Investment trends in venture, licensing, M&A and IPOs
- AI discovery and services partnering
- A new paradigm of landscaping in R&D and BD